



**Neuland**

Experience. Insight. Vision.

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2013**

**PART - I**

Amount in ₹ Million

Sl. No.	Particulars	Quarter Ended 30.09.2013 (Unaudited)	Quarter Ended 30.06.2013 (Unaudited)	Quarter Ended 30.09.2012 (Unaudited)	Half Year Ended 30.09.2013 (Unaudited)	Half Year Ended 30.09.2012 (Unaudited)	Year Ended 31.03.2013 (Audited)
<b>1</b>	<b>Income from Operations</b>						
	(a) Net Sales / Income from Operations						
	Exports	815.24	934.68	854.52	1,749.92	1,782.47	3,323.09
	Domestic	227.61	278.50	323.71	506.11	661.80	1,282.77
	<b>Total</b>	<b>1,042.85</b>	<b>1,213.18</b>	<b>1,178.23</b>	<b>2,256.03</b>	<b>2,444.27</b>	<b>4,605.86</b>
	(b) Other Operating Income	8.12	7.21	2.23	15.33	16.18	33.18
	<b>Total Income from Operations (Net)</b>	<b>1,050.97</b>	<b>1,220.39</b>	<b>1,180.46</b>	<b>2,271.36</b>	<b>2,460.45</b>	<b>4,639.04</b>
<b>2</b>	<b>Expenses</b>						
	(a) Consumption of Raw Materials	582.11	635.29	762.24	1,217.40	1,515.03	2,726.06
	(b) Changes in inventories of finished goods and work in process	(41.79)	46.57	(73.60)	4.78	(27.88)	(34.50)
	(c) Employee Benefit Expense	89.15	96.35	85.11	185.50	171.01	348.83
	(d) Depreciation	37.10	36.52	36.35	73.62	73.61	146.22
	(e) Manufacturing Expenses	116.58	99.36	109.48	215.94	220.13	458.45
	(f) Other Expenses	142.07	114.59	141.43	256.66	248.68	493.29
	<b>Total Expenses</b>	<b>925.22</b>	<b>1,028.68</b>	<b>1,061.01</b>	<b>1,953.90</b>	<b>2,200.58</b>	<b>4,138.35</b>
<b>3</b>	<b>Profit from Operations before Foreign Exchange (gain) / loss and Finance Costs (1-2)</b>	<b>125.75</b>	<b>191.71</b>	<b>119.45</b>	<b>317.46</b>	<b>259.87</b>	<b>500.69</b>
<b>4</b>	Foreign Exchange (gain) / loss (Net)	15.98	22.23	2.55	38.21	24.52	32.46
<b>5</b>	<b>Profit from Operations before Finance Costs (3-4)</b>	<b>109.77</b>	<b>169.48</b>	<b>116.90</b>	<b>279.25</b>	<b>235.35</b>	<b>468.23</b>
<b>6</b>	Finance Costs	63.06	59.01	78.49	122.07	158.17	313.30
<b>7</b>	<b>Profit / (Loss) before Tax (5-6)</b>	<b>46.71</b>	<b>110.47</b>	<b>38.41</b>	<b>157.18</b>	<b>77.18</b>	<b>154.93</b>
<b>8</b>	<b>Tax Expense</b>						
	(a) Current tax	10.77	21.05	7.55	31.82	15.52	30.19
	(b) Deferred Tax	12.28	32.36	-	44.64	-	41.87
	(c) MAT Credit entitlement	(10.77)	(21.05)	-	(31.82)	-	(53.50)
<b>9</b>	<b>Net Profit / (Loss) for the period (7-8)</b>	<b>34.43</b>	<b>78.11</b>	<b>30.86</b>	<b>112.54</b>	<b>61.66</b>	<b>136.37</b>
<b>10</b>	Paid-up Equity Share Capital (Face Value ₹10 per share)	77.16	77.16	77.16	77.16	77.16	77.16
<b>11</b>	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						898.33
<b>12</b>	<b>Earnings per Share (EPS) (in ₹)</b>						
	(a) Basic	4.50	10.22	4.04	14.72	8.07	17.84
	(b) Diluted	4.50	10.21	4.03	14.71	8.06	17.82



**Neuland Laboratories Limited**

Registered Office: Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road no: 2, Banjara hills, Hyderabad - 500 034. AP, India. Tel : +91-40-30211600 Email: neuland@neulandlabs.com

Unit-1 : Survey No: 474, 347, 490/2, 488G & 489A, Bonthapally (V), Veerabhadraswamy Temple Road, Jinnaram (M), Medak Dist - 502313 AP, India, Tel : 08458-392724

Unit-2 : IDA, Pashamylaram, Isnapur Village, Patancheru (M), Medak Dist - 502 319 AP, India, Tel : 08455-302145



Neuland

Experience. Insight. Vision.

**PART - II**

Sl. No.	Particulars	Quarter Ended 30.09.2013 (Unaudited)	Quarter Ended 30.06.2013 (Unaudited)	Quarter Ended 30.09.2012 (Unaudited)	Half Year Ended 30.09.2013 (Unaudited)	Half Year Ended 30.09.2012 (Unaudited)	Year Ended 31.03.2013 (Audited)
<b>A</b>	<b>PARTICULARS OF SHARE HOLDING</b>						
1	Public Shareholding						
	(a) Number of Shares	3,817,199	3,817,199	3,817,199	3,817,199	3,817,199	3,817,199
	(b) Percentage of Shareholding	49.93%	49.93%	49.93%	49.93%	49.93%	49.93%
2	Promoters and Promoter Group Shareholding						
	(a) Pledged / Encumbered						
	-Number of Shares	200,000	200,000	200,000	200,000	200,000	200,000
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	5.22%	5.22%	5.22%	5.22%	5.22%	5.22%
	-Percentage of Shares (as a % of the total share capital of the Company)	2.62%	2.62%	2.62%	2.62%	2.62%	2.62%
	(b) Non-encumbered						
	-Number of Shares	3,627,779	3,627,779	3,627,779	3,627,779	3,627,779	3,627,779
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	94.78%	94.78%	94.78%	94.78%	94.78%	94.78%
	-Percentage of Shares (as a % of the total share capital of the Company)	47.45%	47.45%	47.45%	47.45%	47.45%	47.45%

**B INVESTOR COMPLIANTS**

Particulars	Quarter Ended 30.09.2013
Pending at the beginning of the quarter	1
Received during the quarter	4
Disposed off during the quarter	5
Remaining unresolved at the end of the quarter	0



Neuland Laboratories Limited

Registered Office: Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road no: 2, Banjara hills, Hyderabad - 500 034. AP, India. Tel : +91-40-30211600 Email: neuland@neulandlabs.com

Unit-1 : Survey No: 474, 347, 490/2 , 488G & 489A, Bonthapally (V) , Veerabhadraswamy Temple Road, Jinnaram (M), Medak Dist - 502313 AP, India, Tel : 08458-392724

Unit-2 : IDA, Pashamylaram, Isnapur Village, Patancheru (M), Medak Dist - 502 319 AP, India, Tel : 08455-302145



Neuland

Experience. Insight. Vision.

**NOTES:**

- 1 The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on November 7, 2013, and approved and taken on record at the Board of Directors meeting held on November 8, 2013.
- 2 EPS for the quarters and half year is not annualised.
- 3 The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".
- 4 The statement of assets and liabilities is as follows:

Amount in ₹ Million

Sl No	Particulars	As on 30.09.2013 (Unaudited)	As on 31.03.2013 (Audited)
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	Shareholders' Funds		
	(a) Share Capital	77.16	77.16
	(b) Reserves and Surplus	1,020.76	908.64
		1,097.92	985.80
2	Non-current Liabilities		
	(a) Long-term Borrowings	398.44	511.10
	(b) Deferred Tax Liability	71.71	27.07
	(c) Other Long-term Liabilities	33.30	33.30
	(d) Long-term Provisions	52.65	47.05
		556.10	618.52
3	Current Liabilities		
	(a) Short-term Borrowings	1,418.29	1,353.15
	(b) Trade Payables	832.97	787.42
	(c) Other Current Liabilities	430.01	426.26
	(d) Short-term Provisions	97.68	76.52
		2,778.95	2,643.35
	<b>TOTAL</b>	<b>4,432.97</b>	<b>4,247.67</b>
<b>B</b>	<b>ASSETS</b>		
1	Non-current Assets		
	(a) Fixed Assets	1,681.69	1,712.13
	(b) Non-current Investments	76.41	76.41
	(c) Deferred Tax Asset	-	-
	(d) Long-term Loans and Advances	58.24	55.25
	(e) Other Non-current Assets	79.49	80.95
		1,895.83	1,924.74
2	Current Assets		
	(a) Inventories	1,041.42	921.69
	(b) Trade Receivables	924.94	984.95
	(c) Cash and Bank Balances	6.12	2.84
	(d) Short-term Loans and Advances	448.36	315.32
	(e) Other Current Assets	116.30	98.13
		2,537.14	2,322.93
	<b>TOTAL</b>	<b>4,432.97</b>	<b>4,247.67</b>

- 5 Previous quarter / year figures have been regrouped wherever necessary.

Place: Hyderabad  
Date: November 8, 2013



By Order of the Board  
For Neuland Laboratories Limited

Dr. D.R. Rao

Chairman & Managing Director